Iaso Therapeutics
East Lansing, US · Founded 2018 · Delaware corporation · 2 known investors
Founders & leadership
RF
Robert ForgeyExecutive
XH
Xuefei HuangNamed on SEC filing
HK
Herbert KavunjaNamed on SEC filing
Board
DP
Donald ParfetBoard director
JW
SK
Steve KuemmerieBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$1M disclosed across 2 rounds · 2022–2026
▶$570KraisedJan 2026 · 1 investors · BiotechnologyRule 506(b)
▶$570KraisedJan 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steve KuemmerieDirector
- Robert ForgeyExecutive Officer, Director
- Xuefei HuangExecutive Officer, Director
- Donald ParfetDirector
- Jeffrey WesleyDirector
- Offering amount
- $1.8M
- Amount sold
- $570K
- Minimum investment
- $25K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$437.9KraisedJan 2023 · 5 investors · BiotechnologyRule 506(b)
▶$437.9KraisedJan 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xuefei HuangExecutive Officer, Director
- Herbert KavunjaExecutive Officer
- Jeffrey WesleyDirector
- Donald ParfetDirector
- Robert ForgeyExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $437.9K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapOisin Biotechnologies5 shared keywordsOisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing. Its pipeline targets the biology of aging, with programs in targeted fat removal, muscle building, and longevity biology across aesthetic and longevity medicine.
Alumis4 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
IQVIA4 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with Iaso Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2022 | $978.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $594.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
| National Science Foundation | Phase I | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who are Iaso Therapeutics's investors?
- Iaso Therapeutics's investors include Michigan Rise, WMU Biosciences Research & Commercialization Center.
- How much funding has Iaso Therapeutics raised?
- Iaso Therapeutics has disclosed $1M raised across 2 rounds.
- Where is Iaso Therapeutics headquartered?
- Iaso Therapeutics is headquartered in East Lansing, US.